Lorlatinib Continuation Study

NCT05144997 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small-Cell Lung Cancer
NSCLC

Interventions

DRUG: Lorlatinib

Sponsor

Pfizer